The Impact of Preclinical High Potent P2Y(12) Inhibitors on Decision Making at Discharge and Clinical Outcomes in Patients with Acute Coronary Syndrome

Background: Purinergic signaling receptor Y(12) (P2Y(12)) inhibitors are a fundamental part of pharmacological therapy in acute coronary syndrome (ACS) for preventing recurrent ischemic events. Current guidelines support the use of prasugrel over ticagrelor—however, ticagrelor is widely used for pre...

Descripción completa

Detalles Bibliográficos
Autores principales: Hammer, Andreas, Krammel, Mario, Aigner, Patrick, Pfenneberger, Georg, Schnaubelt, Sebastian, Hofer, Felix, Kazem, Niema, Koller, Lorenz, Steinacher, Eva, Baumer, Ulrike, Hengstenberg, Christian, Niessner, Alexander, Sulzgruber, Patrick
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10299011/
https://www.ncbi.nlm.nih.gov/pubmed/37373788
http://dx.doi.org/10.3390/jcm12124094

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10299011/
https://www.ncbi.nlm.nih.gov/pubmed/37373788
http://dx.doi.org/10.3390/jcm12124094

Ejemplares similares